Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRay Therapeutics, Inc.

About this trial

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.

The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment.

The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.

Eligibility criteria

Qualifiers

Diagnosis of bilateral retinitis pigmentosa (RP) or other retinal dystrophies impacting peripheral vision as confirmed from previous eye examination records

Best-corrected visual acuity between 20/200 to HM in at least one eye.

Reasonably fluent in English or Spanish

Disqualifiers

Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.

Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol

Current pregnancy as reported by patient

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

25 Participants
are grouped into 2 trial groups

Sponsors and collaborators